The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...
More than 15.5 million Americans have tried weight loss injectables, but risks are rising with the proliferation of ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...